2/9/2010-Biogen Idec (NASDAQ:BIIB) reported Q4 EPS of $1.20, beating consensus estimates of $1.05.

Revenues for the quarter rose 5% year-over-year to $1.1 billion, in line with consensus estimates.

For 2010, the company expects EPS to be above $4.55, versus consensus estimates of $4.37.

James C. Mullen, Biogen Idec's President and CEO, commented, "Biogen Idec delivered strong financial and operational performance in 2009. We recorded our sixth consecutive year of double-digit EPS growth, TYSABRI became Biogen Idec's third blockbuster product and we advanced two programs into registrational trials. We are confident that our continued focus on our products, robust pipeline and disciplined use of cash will fuel future earnings growth and drive value for Biogen Idec shareholders."

Contact Chip Brian

SmarTrend analyzes over 5,000 securities simultaneously throughout the trading day and provides its subscribers with trend change alerts in real time. To get a free trial of our trading calls and maximize your trading results, please visit http://www.TradeTheTrend.com.

Get exclusive, actionable insight into how the market is expected to trend prior to market open with our free morning newsletter. Sign up at www.TradeTheTrend.com/signup.html